An unexpected role of cholesterol sulfotransferase and its regulation in sensitizing mice to acetaminophen induced liver injury

Yunqi An, Pengcheng Wang, Pengfei Xu, Hung-Chun Tung, Yang Xie, Levent Kirisci, Meishu Xu, Songrong Ren, Xin Tian, Xiaochao Ma, Wen Xie#

Center for Pharmacogenetics and Department of Pharmaceutical Sciences (Y.A., P.W., P.X., H-C.T., Y.X., L.K., M.X., S.R., X.T., X.M., W.X.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Pharmacy (X.T.), The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Department of Pharmacology and Chemical Biology (W.X.), University of Pittsburgh, Pittsburgh, Pennsylvania
Running Title: SULT2B1b sensitizes mice to APAP toxicity

#Corresponding Author: Department of Pharmaceutical Sciences, 306 Salk Pavilion, University of Pittsburgh, Pittsburgh, PA 15261. E-mail: wex6@pitt.edu

Number of text pages: 38

Number of figures: 5

Number of references: 48

Number of words in Abstract: 160

Number of words in Introduction: 750

Number of words in Discussion: 830

DISCLOSURE STATEMENT: The authors have nothing to disclose

Key words: sulfortransferase; HNF4α; acetaminophen; liver injury

Abbreviations:

ALF, acute liver failure; ALT, alanine aminotransferase; APAP, acetaminophen; APAP-CYS, APAP-cysteine; AST, aspartate aminotransferase; Fabp, fatty acid binding protein; GSH, glutathione; GST, glutathione S-transferase; HNF4α, hepatic nuclear factor 4α; KO, knockout; LXR, liver X receptor; NAPQI, N-acetyl-p-benoquinone-imine; SULT, sulfortransferase; SULT2B1b, cholesterol sulfortransferase; TG, transgenic; UGT, UDP-glucuronosyltransferase
Abstract

Overdose of acetaminophen (APAP) is the leading cause of acute liver failure (ALF) in the United States. The sulfotransferase-mediated sulfation of APAP is widely believed to a protective mechanism to attenuate the hepatotoxicity of APAP. The cholesterol sulfotransferase SULT2B1b is best known for its activity in catalyzing the sulfoconjugation of cholesterol to synthesize cholesterol sulfate. SULT2B1b can be transcriptionally and positively regulated by the hepatic nuclear factor 4α (HNF4α). In this study, we uncovered an unexpected role for SULT2B1b in APAP toxicity. Hepatic overexpression of SULT2B1b sensitized mice to APAP-induced liver injury, whereas ablation of the Sult2B1b gene in mice conferred resistance to the APAP hepatotoxicity. Consistent with the notion that Sult2B1b is a transcriptional target of HNF4α, overexpression of HNF4α sensitizes mice or primary hepatocytes to APAP-induced hepatotoxicity in a Sult2B1b dependent manner. We conclude that the HNF4α-SULT2B1b axis has a unique role in APAP-induced acute liver injury, and SULT2B1b induction might be a risk factor for APAP hepatotoxicity.
Introduction

Acetaminophen (APAP) or Tylenol is a commonly used drug to reduce fever and relieve pain. However, APAP overdoses result in approximately 500 people dead each year in the United States (Lee, 2008). APAP overdose causes most of the acute liver failure (ALF), especially in the United States (Furuta et al., 2016). At therapeutic doses, about 3% of APAP is excreted as the parent drug via the urine. More than 90% of APAP can be rapidly metabolized into the nontoxic compounds by phase II conjugating enzymes in the liver, two thirds through glucuronidation by UDP-glucuronosyltransferases (UGTs) and one third through sulfation by sulfotransferases (SULTs). 5%-9% of APAP is bioactivated to a highly reactive toxic metabolite, N-acetyl-p-benzoquinone imine (NAPQI), by phase I cytochrome P450 enzymes (CYPs), especially the CYP2E1 (Dahlin et al., 1984; Mannery et al., 2010; Potter et al., 1973). NAPQI has a short half-life, because it can be rapidly eliminated by conjugation with glutathione (GSH), before being excreted via the urine as mercapturic acid and cysteine conjugates (Du et al., 2016). When APAP overdose occurs, the glucuronidation and sulfation pathways are saturated, so more APAP is metabolized by CYPs to NAPQI. Excessive NAPQI depletes intracellular GSH. Accumulated
NAPQI binds to other cellular proteins, leading to mitochondrial oxidative stress, nuclear DNA fragmentation, and hepatocyte death (Beger et al., 2015; Du et al., 2016). The oral formulation of N-acetylcysteine (NAC) is an antidote approved for treating the overdose of APAP. NAC is nearly fully hepatoprotective when it is administered to patients within 8 hours after an acute APAP overdose (Wolf et al., 2007; Yoon et al., 2016). However, NAC has a narrow therapeutic window (Nam et al., 2017). There are no effective treatment options for severe ALF except for liver transplantation. Thus, new therapeutics that target APAP overdose are urgently needed.

The human SULT2 family, also called hydroxysteroid-SULT family, is comprised of two genes, known as SULT2A1 and SULT2B1. They catalyze the sulfo-conjugation of many compounds and differ in tissue distribution and substrate specificity (Falany and Rohn-Glowacki, 2013). Because of the length of transcripts, SULT2B1 is divided into two isoforms, SULT2B1a and SULT2B1b. At the transcript level, the expression of SULT2B1a and SULT2B1b is very similar, but only the SULT2B1b protein can be detected in humans (Falany et al., 2006). SULT2B1b appears to be the major functional SULT2B1 isoform. SULT2B1b is specific for the sulfation of
3-hydroxysteroids (Falany and Rohn-Glowacki, 2013). Subsequent studies have reported crucial roles of SULT2B1b in regulating liver functions and impacting the pathogenesis of diseases.

SULT2B1b is induced by liver regeneration in a mouse model of partial hepatectomy (Lo Sasso et al., 2010). SULT2B1b increases the proliferation of liver cancer cells which may have contributed to the progression of HCC (Yang et al., 2013). Oxysterols, the endogenous ligands for the liver X Receptor (LXR), are substrates of SULT2B1b (Bai et al., 2011; Bensinger et al., 2008). Upregulation of SULT2B1b inhibited lipogenesis by sulfonating and deactivating the LXR-activating oxysterols (Bai et al., 2011), and aggravated 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-induced liver damage by suppressing oxysterol-induced LXR activation (Wang et al., 2017). SULT2B1b has been reported to be regulated by several nuclear receptors, such as CAR (Dong et al., 2009), VDR (Seo et al., 2013), and PPARs (Jiang et al., 2005).

We recently reported that SULT2B1b can inhibit hepatic gluconeogenesis by suppressing the gluconeogenic activity of hepatocyte nuclear factor 4α (HNF4α) (Shi et al., 2014). HNF4α promotes gluconeogenesis by upregulating PEPCK and G6Pase gene expression (Rhee et al.,...
Mechanistically, SULT2B1b and its enzymatic product cholesterol sulfate suppress gluconeogenesis by inhibiting acetyl-CoA synthetase (Acss) gene expression, leading to reduced acetylation and nuclear exclusion of HNF4α (Shi et al., 2014). More recently, we reported that the SULT2B1b itself is a transcriptional target gene of HNF4α (Bi et al., 2018). The establishment of SULT2B1b as a HNF4α target gene called up our hypothesis that the induction of SULT2B1b by HNF4α involves in a negative feedback to inhibit the gluconeogenic activity of HNF4α (Bi et al., 2018). Although several SULT isoforms and their regulations have been implicated in APAP toxicity (Saini et al., 2011), it is unknown whether SULT2B1b plays a role in APAP hepatotoxicity and if so, whether HNF4α can also impact the hepatotoxicity of APAP by its positive regulation of SULT2B1b.

In this study, we demonstrated that overexpression of hepatic SULT2B1b sensitized mice to APAP-induced liver damage, whereas ablation of Sult2B1b attenuated mice from APAP toxicity. A forced expression of Hnf4α aggravates APAP hepatotoxicity in a Sult2B1b dependent manner.
Our results pointed to SULT2B1b induction as a potential risk factor for APAP-induced acute liver damage.
Materials and Methods

Animals. The Sult2B1b knockout mice (Strain # 018773) in C57BL/6J-129/SvJ mixed background were purchased from the Jackson Laboratory (Bar Harbor, ME), and wild type (WT) mice of the same mixed genetic background were used as the controls. The liver-specific FABP-SULT2B1b transgenic mice in the C57BL/6J background were created and characterized as previously described (Shi et al., 2014), and WT C57BL/6J mice were used as the controls. All mice used in this study were 6 to 8 weeks old female mice. The use of animals in this study complied with all relevant federal guidelines and institutional policies.

Induction of APAP-induced liver injury. APAP was dissolved in 0.5% methyl cellulose solution. Before receiving a single dose of 200 mg/kg APAP by gavage, all of the mice were fasted for 16 hours. Food was given back to mice three hours after the APAP treatment. The mice were sacrificed 24 hours post APAP treatment (Saini et al., 2011). Liver tissues and serum samples were collected for biochemical analysis and histology. All chemicals mentioned in this study were bought from Sigma (St. Louis, MO).
**Histology.** For hematoxylin and eosin (H&E) staining, liver samples were fixed in 10% paraformaldehyde, embedded in paraffin, sectioned at 4 µm, and stained. For immunohistochemistry analysis, standard immunohistochemical procedures were performed using a Ki67 antibody purchased from Abcam (Cambridge, MA). APO-BRDU (TUNEL) Apoptosis Kit from Novus (Littleton, CO) was used to examine dying cells with exposed or fragmented DNA ends.

**Serum and liver tissue chemistry.** ALT and AST analysis in the serum (Lu et al., 2015) and primary hepatocytes (Miyakawa et al., 2015) were performed using commercial assay kits from Stanbio Laboratory (Boerne, TX). The ratio of ALT in the medium of primary hepatocytes to ALT in the lysates of primary hepatocytes was calculated as the percentage of ALT release. The concentrations of GSH and GSSG in the liver tissue samples were measured by Assay Kit from BioAssay Systems (Hayward, CA).
**Real-time PCR.** Total RNA in the liver was isolated by the TRizol reagent from Thermo Fisher Scientific (Pittsburgh, PA). Reverse transcription was conducted with random hexamer primers and Superscript RT III enzyme from Invitrogen. The ABI 7300 Real-Time PCR System was used to perform SYBR Green-based real-time PCR. The quantity of mRNA measured was normalized to the cyclophilin gene expression.

**Western blot analysis.** Western blotting was conducted as described previously (Shi et al., 2014). The primary antibodies for Hnf4α (Cat # MA1-199) and Sult2B1b (sc-67103) were ordered from Thermo Fisher Scientific and Santa Cruz (Santa Cruz, CA), respectively.

**Isolation, culture and adenoviral infection of primary hepatocytes from mice.** As described previously (Jiang et al., 2014), primary hepatocytes were extracted from 8 to 10 weeks old mice. Briefly, the mice liver was first perfused with Hanks’ buffered salt solution containing 0.1 M HEPES and 0.5 mM EGTA at the speed of 5 ml/min for 5–10 minutes and then perfused with L-15 medium containing 20 mg/ml liberase, 1.8 mM CaCl₂, and 0.1 M HEPES from Roche.
(Indianapolis, IN). When the perfusion was completed, the dissociated hepatocytes were filtered through 50-mm tissue cell strainer and centrifuged at 500 rpm for 3 minutes at 4°C to collect. Hepatocytes were seeded onto 6-well plates coated with type 1 collagen in William E medium containing 5% fetal bovine serum. After 2 hours, the medium was replaced by HepatoZYME-SFM medium (GIBCO, Grand Island, NY). To overexpress Hnf4α, the primary hepatocytes were infected with adenovirus expressing Hnf4α (Ad-Hnf4α), or the control virus (Ad-Ctrl). Both virus were given as presents by Dr. Yanqiao Zhang from the Northeast Ohio Medical University (Yin et al., 2011).

**APAP metabolic analysis.** APAP metabolic analysis was performed as described (Cheng et al., 2009). In brief, 100 mg of liver tissue samples were homogenized in 500 µl of water. 200 µl of acetonitrile:methanol (1:1, v/v) was added to 100 µl of each homogenate. The mixture was vortexed and centrifuged (15,000 g for 10 min), and the supernatant was transferred to a new 1.5mL Eppendorf vial for a second centrifugation (15,000 g for 10 min). 20 µl of the serum samples were added by 80 µl of methanol. The prepared mixture was vortexed and centrifuged at
15,000 g for 10 min. Each supernatant from above was transferred to an autosampler vial and analyzed by ultraperformance liquid chromatography coupled with time-of-flight mass spectrometry (UPLC-TOFMS) from Waters Corporation (Milford, MA). Metabolites was separated by an Acquity UPLC BEH C18 column (2.1 × 50 mm, 1.7 µm; Waters, Milford, MA) using a gradient ranging from 5% to 95% aqueous acetonitrile containing 0.1% formic acid over a 6-min run. TOFMS was operated in positive mode with electrospray ionization and the MS data were acquired in centroid format (50-1,000 Da). The capillary and cone voltages were set as 0.8 kV and 40 V, respectively. The source temperature was set as 150°C. The desolvation gas (800 l/hour) was set at 500°C. APAP and its major metabolites (APAP-sulfate, APAP-glucuronide, APAP-GSH, and APAP-Cys) were identified by high-resolution accurate mass and tandem MS/MS fragmental analysis. The peak areas were quantified to represent the signal intensities. All data were acquired using Masslynx™ V4.1 software and quantified using Quanlynx™ V4.1 (Waters Corp., Milford, MA).
**Statistical analysis.** All the data are expressed as means ± standard error of the mean (SEM).

Comparisons of two groups were evaluated by the unpaired two-tailed Student’s *t* test, and comparisons of three or more groups were performed by one-way MANOVA. The MANOVA analysis was carried out by SPSS version 24.0. to understand if there were differences between the genotype on the two dependent variables, AST and ALT. The criterion for statistical significance was a *P* value of less than 0.05 unless otherwise indicated. Some results were applied Bonferroni correction to control the type 1 errors, and accepted a *P* value of less than 0.005 (for Figures 1 and 2, in which 10 comparisons were tested in the same samples), 0.017 (for Figure 3, in which 3 comparisons were tested in the same samples), 0.003 (for Figure 5A-C, in which 15 comparisons were tested in the same samples), 0.025 (for Figure 5E, in which 2 comparisons were tested in the same samples), or 0.01 (for Figure 5F, in which 5 comparisons were tested in the same samples).
Results

**Transgenic overexpression of SULT2B1b in the liver aggravates APAP-induced liver injury**

The creation and characterization of transgenic (TG) mice that overexpress the cholesterol sulfotransferase (SULT2B1b) in the liver under the rat fatty acid binding protein (FABP) gene promoter were previously reported by us (Shi et al., 2014). To investigate whether SULT2B1b plays a role in APAP hepatotoxicity, we treated the TG mice with a single dose of APAP (200 mg/kg by gavage) after a 16-hour fasting (Saini et al., 2011). Twenty-four hours after the treatment, liver tissue and serum samples were harvested for analysis. H&E staining revealed that the livers of the TG mice displayed more severe damage compared to the wild type (WT) mice. The liver histology of the vehicle-treated TG mice appeared normal. Upon the APAP treatment, the TG mice showed a quantifiably more extensive necrotic liver damage than their WT counterparts (Fig. 1A). In addition, APAP-treated TG mice had elevated serum levels of alanine aminotransferase (ALT) (Fig. 1B) and aspartate aminotransferase (AST) (Fig. 1C) activity compared to APAP-treated WT mice. In APAP-induced liver injury, it is believed that
overdose of APAP is metabolized by CYPs to reactive intermediate NAPQI, which depletes GSH, binds to cellular proteins and induces nuclear DNA fragmentation, leading to necrotic hepatocyte death (Hinson et al., 2010). So, we assessed nuclear DNA fragmentation by TUNEL staining. The TUNEL staining in APAP-treated TG mice was increased (Fig. 1D), consistent with the increased liver damage in this genotype. It is known that liver regeneration is important for survival after APAP overdose (Bhushan et al., 2014), because hepatic cell necrosis eventually induces liver regeneration (Guicciardi et al., 2013). Usually, more necrosis is followed by more cell proliferation. Therefore, we evaluated the expression of cell proliferation and cell cycle related genes in the liver by real-time PCR. The expression of proliferating cell nuclear antigen (Pcna) of TG mice was significantly higher than the WT mice (Fig. 1E), consistent with the notion that TG mice had more liver damage than WT mice. Furthermore, the hepatic expression of inflammatory cytokine genes interleukin-6 (Il-6) and interleukin-1β (Il-1β) in TG mice was significantly higher than that in WT mice after the APAP treatment (Fig. 1F).

Ablation of Sult2B1b protects mice from APAP-induced liver damage
To assess whether Sult2B1b ablation affects APAP-induced liver injury, we treated Sult2B1b knockout (KO) mice with a single dose of 200 mg/kg APAP. The KO mice showed less liver damage compared to the WT mice. The WT mice showed remarkable necrotic liver damage at 24 hours post-APAP treatment as expected. In contrast, the KO mice showed less liver damage as evidence by smaller necrotic area (Fig. 2A), decreased serum levels of ALT (Fig. 2B) and AST (Fig. 2C), and decreased TUNEL staining (Fig. 2D). The mRNA expression of Pcna and Ccnd 1 was significantly decreased in APAP-treated KO mice (Fig. 2E), consistent with an attenuated liver injury in this genotype. The decreased hepatocyte proliferation in APAP-treated KO mice was also supported by a decreased immunostaining of the hepatocyte proliferation marker Ki67 (Fig. 2F). Consistently and compared to the WT mice, the mRNA expression of Il-1β was decreased in APAP-treated KO mice (Fig. 2G).

Overexpression of Hnf4α induces Sult2B1b and sensitizes mice or primary hepatocytes to APAP-induced injury
We recently reported that Sult2B1b is a transcriptional target of Hnf4α (Bi et al., 2018). Having shown that overexpression of SULT2B1b was sufficient to sensitize mice to APAP-induced liver injury, we wanted to determine whether up-regulation of Sult2B1b by HNF4α in the mouse liver will have a similar sensitizing effect on APAP-induced liver injury. In this experiment, WT mice were infected with adenovirus expressing Hnf4α (Ad-Hnf4α) or the control virus (Ad-Ctrl) for one week before being treated with APAP. The overexpression Hnf4α and expected induction of Sult2B1b were confirmed by Western blotting (Fig. 3A). Compared to Ad-Ctrl infected mice, the Ad-Hnf4α infected mice displayed more severe liver injury as evidence by the gross appearance and increased necrotic area (Fig. 3B), and increased serum levels of ALT and AST (Fig. 3C).

The in vivo results were further supported by in vitro results using primary hepatocytes isolated from WT mice. In this experiment, primary hepatocytes infected with Ad-Ctrl or Ad-Hnf4α were treated with 5 mM APAP for 24 hours. The overexpression of Hnf4α and induction of Sult2B1b were proved by real-time PCR (Fig. 3D). Compared to Ad-Ctrl infected hepatocytes, Ad-Hnf4α infected hepatocytes showed an increased APAP-responsive release of ALT (Fig. 3E), and a decreased cell viability as shown by the MTT assay (Fig. 3F).
The sensitizing effect of HNF4α on APAP-induced injury is Sult2B1b dependent

To determine whether the sensitizing effect of HNF4α on APAP-induced liver injury in vivo is Sult2B1b dependent, we infected Sult2B1b KO mice with Ad-Ctrl or Ad-Hnf4α before challenging them with APAP. The overexpression of Hnf4α was verified by Western blotting (Fig. 4A). Upon the APAP treatment, the injury between Ad-Ctrl infected and Ad-Hnf4α infected KO mice was not different, because neither the gross appearance and necrotic area (Fig. 4B), nor the serum levels of ALT and AST (Fig. 4C) were different between these two groups of KO mice. The dependence of Sult2B1b in the sensitizing effect of Hnf4α was also confirmed in primary hepatocytes isolated from the KO mice. The adenoviral overexpression of Hnf4α in KO primary hepatocytes was confirmed by real-time PCR (Fig. 4D). The KO primary hepatocytes infected with Ad-Ctrl or Ad-Hnf4α showed comparable release of ALT (Fig. 4E) and cell viability as shown by the MTT assay (Fig. 4F). These results suggested that the sensitizing effect of HNF4α on APAP-induced injury is Sult2B1b dependent both in vivo and in vitro.
**Mechanism by which SULT2B1b sensitizes mice to APAP-induced liver injury**

To understand the mechanism by which SULT2B1b sensitizes mice to APAP-induced liver injury, we profiled the expression of genes known to play a role in APAP hepatotoxicity. Among the phase I and phase II enzymes, only the expression of Ugt1 was dramatically induced in APAP-treated TG mice, while the expressions of other APAP metabolizing enzymes showed no significant difference in either the TG or KO mice (Fig. 5A). The expression of a panel of nuclear receptors that are known to play a role in APAP hepatotoxicity, including CAR (Zhang et al., 2002), FXR (Lee et al., 2010), LXRα (Saini et al., 2011), PXR (Guo et al., 2004) and RXR (Dai et al., 2005), was not affected by the SULT2B1b transgene or knockout either (Fig. 5B). We have previously reported that activation of LXRα attenuated APAP-induced liver injury (Saini et al., 2011). We found the expressions of LXR as well as its target genes were not affected in APAP-treated TG or KO mice (Fig. 5C). The total hepatic GSH content in APAP-treated TG mice was remarkably decreased, whereas the ratio of GSSG/GSH was significantly increased in TG mice (Fig. 5D, top), consistent with the increased sensitivity to APAP-induced liver injury in this genotype. However, the total GSH level and the GSSG/GSH ratio between WT and KO
mice were not different (Fig. 5D, bottom). When the APAP metabolites were analyzed, we found the serum concentrations of APAP-sulfate and APAP-glucuronide were increased in TG mice 24 hours after the APAP treatment (Fig. 5E), consistent with the expression of the SULT transgene and induction of Ugt1 in this genotype. Interestingly, at 1 hour post-APAP treatment, the transgene had little effect on the hepatic concentrations of parent APAP, APAP-sulfate, APAP-glucuronide, APAP-GSH, or APAP-Cys (Fig. 5F).
**Discussion**

Overdose of APAP could eventually lead to acute liver failure. Although the mechanisms of APAP-induced liver injury have been extensively studied, factors that can affect the progression of APAP-induced liver disease or improve the liver recovery are less investigated. Identification of the related pathogenic factors will provide novel therapeutic approaches for the treatment of APAP overdose.

SULT2B1b is a hydroxysteroid sulfotransferase that plays important roles in diverse cell types and tissues, such as suppressing lipogenesis (Ren and Ning, 2014) and gluconeogenesis (Bi et al., 2018; Shi et al., 2014), and promoting the hepatocyte proliferation (Yang et al., 2013), affecting prostate and colorectal cancer cells (Vickman et al., 2016), and suppressing the T cell receptor signaling (Wang et al., 2016). In this study, we found a novel function of SULT2B1b in APAP-induced liver toxicity. Specifically, hepatic transgenic overexpression of SULT2B1b exacerbated APAP-induced acute liver injury, whereas ablation of the Sult2B1b gene in mice conferred protection to APAP hepatotoxicity. The sensitizing effect of SULT2B1b on APAP-induced liver
injury is a surprise, considering that sulfation of APAP has been established as an important mechanism for the detoxification of APAP. For example, we have previously reported the attenuation of APAP toxicity by the activation LXRα (Saini et al., 2011), which was associated with the induction of Sult2a1.

The mechanism by which SULT2B1b sensitizes mice to APAP toxicity remains to be clearly defined. APAP may not be a substrate of SULT2B1b in vitro, according to a published report (Yamamoto et al., 2015). However, we cannot exclude the possibility that APAP at our used pharmacological concentrations is a substrate of SULT2B1b in vivo, a notion supported by the increased serum concentration of APAP-sulfate in TG mice 24 hours after the APAP treatment (Fig. 5E). Knowing that SULT2B1b suppresses LXR activity by sulfonating and deactivating the endogenous LXR agonists (Bensinger et al., 2008; Villablanca et al., 2010), and activation of LXR accelerates APAP clearance and attenuates APAP toxicity (Saini et al., 2011), we initially hypothesized that the sensitizing effect of SULT2B1b might be due to the inhibition of LXR. However, we found the expression of LXRα and its primary target genes was not affected by the
transgene (Fig. 5C). SULT2B1b transgene or ablation also had little effect on the expression of a panel of nuclear receptors and CYP enzymes that are known to impact APAP metabolism and toxicity, except that Ugt1 was up-regulated in APAP-treated TG mice for a yet to be defined reason (Fig. 5). The decreased GSH level in APAP-treated TG mice (Fig. 5D) suggested that overexpression of SULT2B1b may have compromised the replenishment of GSH via a yet to be characterized mechanism. The hepatic concentrations of parent APAP, APAP-sulfate, APAP-glucuronide and APAP-Cys at 1 hour post-APAP treatment showed no difference between the WT and TG mice. The serum concentrations of two nontoxic metabolites APAP-sulfate and APAP-glucuronide were elevated at 24 hours post-APAP in the TG mice, but they were not affected in the KO mice. These results indicate that the effect of the SULT2B1b transgene on APAP metabolism might be time dependent. A future detailed pharmacokinetic analysis is necessary to conclude the effect of SULT2B1b on APAP metabolism.

The sensitizing effect of HNF4α is also intriguing. On one hand, the sensitization was predictable based on the positive regulation of Sult2B1b by HNF4α as we have recently reported.
(Bi et al., 2018), and the sensitizing effect of HNF4α was Sult2B1b dependent (Fig. 4). On the other hand, the aggravation of APAP-induced liver injury by HNF4α was a surprise, considering the reported hepatoprotective effect of HNF4α in liver injury induced by xenobiotic toxicants (Beggs et al., 2016), alcohol and MCD diet (Xu et al., 2016), as well as in the context of NASH, ALF and HCC (Baciu et al., 2017; Hang et al., 2017; Shi et al., 2014; Vallianou et al., 2016). To our knowledge, it is the first demonstration that HNF4α aggravated APAP-induced liver injury through its transcriptional regulation of SULT2B1b. It has been reported that HNF4α is critically involved in PXR- and CAR-mediated transcriptional activation of CYP3A (Tirona et al., 2003), and activation of PXR and CAR and the induction of CYP3A are known to sensitize mice to APAP toxicity (Cheng et al., 2009; Guo et al., 2004; Zhang et al., 2002). Although the expression of PXR, CAR and Cyp3a11 was not affected in APAP-treated TG or KO mice, we cannot exclude the possibility that PXR, CAR and Cyp3a may play a role in mediating the sensitizing effect of HNF4α on APAP toxicity. Female mice were used in this study. Our study focused on APAP toxicity in terms of its metabolism. It has been reported that APAP
metabolism does not contribute to gender difference in the event of APAP overdose (Dai et al., 2006). Further studies are needed to prove whether the phenotype is sex specific.

In summary, we have uncovered a novel function of SULT2B1b and its regulation by HNF4α in APAP-induced acute liver injury. Our results suggest that SULT2B1b induction might be a risk factor for APAP hepatotoxicity. This notion is consistent with the report that nonalcoholic fatty liver disease (NAFLD) sensitized rodents to APAP-induced liver injury (Michaut et al., 2014), because NAFLD and its associated metabolic liver disease induce the hepatic expression of Sult2B1b (Shi et al., 2014).

**Author contributions**

Participated in research design: An and Xie.

Conducted experiments: An, Wang, P Xu, Tung, M Xu, Ren and Tian.

Performed data analysis: An, Wang, Y. Xie, Kirisci, and W. Xie.

Wrote or contributed to the writing of the manuscript: An, Ma and Xie.
Acquired funding: Xie.
References


Footnotes

The work was supported in part by the National Institutes of Health [Grants DK083952, ES023438]. W.X. was supported in part by the Joseph Koslow endowed Chair Professorship from the University of Pittsburgh School of Pharmacy.
Figure legends

Figure 1. Transgenic overexpression of SULT2B1b in the liver aggravates APAP-induced liver injury. (A) Representative H&E staining on liver paraffin sections from WT and SULT2B1b TG mice treated with vehicle (left, original magnification ×100) or APAP (middle, original magnification ×100) for 24 hours. Shown on the right is enlarged view of boxed region in middle panels highlighting the APAP-induced centrilobular necrosis. Shown on the bottom left is the quantification of the necrotic areas. n=5 per group. (B and C) Serum levels of ALT (B) and AST (C) in WT and TG mice treated with vehicle or APAP. (D) Representative images of TUNEL staining in liver sections from WT and TG mice at 24 hours after the vehicle or APAP treatment (original magnification ×200). (E) Relative hepatic mRNA expression of Pena, Ki67, C-myc, Ccnd1, and Ccne1. (F) Relative hepatic mRNA expression of Il-6 and Il-1β. Data are expressed as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.005 (considered statistically significant) upon Bonferroni correction, compared to WT within the same drug treatment (B and C) or the same gene (E and F) as labeled.
Figure 2. Ablation of Sult2B1b protects mice from APAP-induced liver injury. (A)

Representative H&E staining on liver paraffin sections from WT and Sult2B1b KO mice treated with vehicle (left, original magnification ×100) or APAP (middle, original magnification ×100) for 24 hours. Shown on the right is enlarged view of boxed region in middle panels highlighting the APAP-induced centrilobular necrosis. Shown on the bottom left is the quantification of the necrotic areas. n=3 for WT-vehicle and KO-vehicle, n=8 for WT-APAP and KO-APAP. (B and C) Serum levels of ALT (B) and AST (C) in WT and KO mice treated with vehicle or APAP. (D) Representative images of TUNEL staining in liver sections from WT and KO mice at 24 hours after the vehicle or APAP treatment (original magnification ×200). (E) Relative hepatic mRNA expression of Pcna, Ki67, C-myc, Ccnd1, and Ccne1. (F) The expression of Ki67 was detected by immunohistochemistry with arrows indicating the positive stainings. (G) Relative hepatic mRNA expression of Il-6 and Il-1β. Data are expressed as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.005 (considered statistically significant) upon Bonferroni correction, compared to WT within the same drug treatment (B and C) or the same gene (E and G) as labeled.
Figure 3. Overexpression of Hnf4α induces Sult2B1b and sensitizes mice or primary hepatocytes to APAP-induced injury. (A) Hepatic expression of Sult2B1b and Hnf4α in WT mice infected with Ad-Ctrl or Ad-Hnf4 and treated with APAP was measured by Western blot analysis. n=3 per group. (B) Representative gross appearance (top) and H&E staining on liver paraffin sections of Ad-Ctrl+APAP and Ad-Hnf4+APAP WT mice (middle, original magnification ×100), and enlarged view of boxed region in middle panels highlighting the APAP-induced centrilobular necrosis (bottom). Shown below is the quantification of the necrotic areas. n=3 for Ad-Ctrl, n=5 for Ad-Hnf4. (C) Serum levels of ALT and AST in WT mice infected with Ad-Ctrl or Ad-Hnf4α. (D) The mRNA expression of Hnf4α and Sult2B1b in WT primary hepatocytes infected with Ad-Ctrl or Ad-Hnf4α. (E) The percentage of ALT release from WT primary hepatocytes infected with Ad-Ctrl or Ad-Hnf4α and treated with 5 mM APAP for 24 hours. (F) MTT assay on primary hepatocytes described in (E). Data are expressed as mean ± SEM. *, P < 0.05, **, P < 0.017 (considered statistically significant) upon Bonferroni correction, all compared to Ad-Ctrl as labeled.
Figure 4. The sensitizing effect of HNF4α on APAP-induced injury is Sult2B1b dependent.

(A) Hepatic expression of Sult2B1b in Sult2B1b KO mice infected with Ad-Ctrl or Ad-Hnf4 and treated with APAP was measured by Western blot analysis. n=3 per group. (B) Representative gross appearance (top) and H&E staining on liver paraffin sections of Ad-Ctrl+APAP and Ad-Hnf4+APAP KO mice (middle, original magnification ×100), and enlarged view of boxed region in middle panels highlighting the APAP-induced centrilobular necrosis (bottom). Shown below is the quantification of the necrotic areas. n=3 for Ad-Ctrl, n=5 for Ad-Hnf4. (C) Serum levels of ALT and AST in KO mice infected with Ad-Ctrl or Ad-Hnf4α. (D) The mRNA expression of Hnf4α in KO primary hepatocytes infected with Ad-Ctrl or Ad-Hnf4α. (E) The percentage of ALT release from KO primary hepatocytes infected with Ad-Ctrl or Ad-Hnf4α and treated with 5 mM APAP for 24 hours. (F) MTT assay on primary hepatocytes described in (E). Data are expressed as mean ± SEM. n.s., statistically not significant, all compared to Ad-Ctrl as labeled.
Figure 5. Mechanism by which SULT2B1b sensitizes mice to APAP-induced liver injury.

(A and B) Relative mRNA expression of a panel of Phase I and Phase II enzymes (A) and a panel of nuclear receptors (B) in the livers of WT, SULT2B1b TG and KO mice treated with APAP. n=3 per group. (C) Relative mRNA expression of LXRα and its target genes Fas, Scd1 and Srebp-1c in livers from WT, TG and KO mice treated with APAP. n=3 per group. (D) Total liver GSH content and GSSG/GSH ratio in WT, TG and KO mice treated with APAP. n=3 per group. (E) The contents of APAP-sulfate and APAP-glucuronide in the serum from WT and TG mice at 24 hours after the APAP treatment. n=3 per group. (F) The contents of parent APAP, APAP-sulfate, APAP-glucuronide and APAP-Cys in the liver from WT and TG mice at 1 hour post-APAP treatment. n=3 per group. Data are expressed as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.003 (considered statistically significant) upon Bonferroni correction for (A), (B) and (C); *, P < 0.05; **, P < 0.01 (considered statistically significant) for (D); *, P < 0.05, **, P < 0.025 (considered statistically significant) upon Bonferroni correction for (E); and *, P < 0.01 (considered statistically significant) upon Bonferroni correction for (F); n.s., statistically not
significant, all compared to WT-APAP within the same gene (A-C) or the same parameter (D-F) as labeled.
Figure 1

A. Vehicle vs. APAP treatment in WT and SULT2B1b TG mice.

B. Necrotic area (%) comparison between WT and TG groups.

C. ALT and AST levels in WT and TG groups under Vehicle and APAP treatment.

D. Histological images in WT and SULT2B1b TG under Vehicle and APAP treatment.

E. Relative mRNA expression of pro-inflammatory genes (Pcna, Ki67, c-Myc, Ccnd1, Ccne1) in WT and TG groups under APAP treatment.

F. Relative mRNA expression of cytokines (Il-6, Il-1β) in WT and TG groups under APAP treatment.
Figure 2

A

Vehicle

APAP

WT

Sul2B1b KO

B

Necrotic area (%)

WT

KO

C

ALT

WT

KO

AST

WT

KO

D

Vehicle

APAP

WT

KO

E

Relative mRNA expression

PCNA

K67

c-Myc

CCnd1

CCne1

F

Vehicle

APAP

WT

KO

G

Relative mRNA expression

IL-6

IL-1β
Figure 3

A

<table>
<thead>
<tr>
<th></th>
<th>Ad-Ctrl+APAP</th>
<th>Ad-Hnf4α+APAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sult2B1b</td>
<td>![Image]</td>
<td></td>
</tr>
<tr>
<td>Hnf4α</td>
<td>![Image]</td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td>![Image]</td>
<td></td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th></th>
<th>Ad-Ctrl+APAP</th>
<th>Ad-Hnf4α+APAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>![Image]</td>
<td>![Image]</td>
<td></td>
</tr>
</tbody>
</table>

C

<table>
<thead>
<tr>
<th></th>
<th>ALT</th>
<th>AST</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ad-Ctrl</td>
<td>500</td>
<td>200</td>
</tr>
<tr>
<td>Ad-Hnf4α</td>
<td>1500</td>
<td>800</td>
</tr>
</tbody>
</table>

D

<table>
<thead>
<tr>
<th></th>
<th>Relative mRNA expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hnf4α</td>
<td>![Image]</td>
</tr>
<tr>
<td>Sult2B1b</td>
<td>![Image]</td>
</tr>
</tbody>
</table>

E

<table>
<thead>
<tr>
<th></th>
<th>ALT release (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ad-Ctrl</td>
<td>50</td>
</tr>
<tr>
<td>Ad-Hnf4α</td>
<td>80</td>
</tr>
</tbody>
</table>

F

<table>
<thead>
<tr>
<th></th>
<th>Absorbance (590 nm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ad-Ctrl</td>
<td>0.60</td>
</tr>
<tr>
<td>Ad-Hnf4α</td>
<td>0.20</td>
</tr>
</tbody>
</table>
Figure 4

A

<table>
<thead>
<tr>
<th></th>
<th>Ad-Ctrl+APAP</th>
<th>Ad-Hnf4α+APAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hnf4α</td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

C

ALT  | ADH-Ctrl   | ADH-hnf4α+APAP | n.s. | ADH-Ctrl | ADH-hnf4α+APAP | n.s. |
| AST  | ADH-Ctrl   | ADH-hnf4α+APAP | n.s. | ADH-Ctrl | ADH-hnf4α+APAP | n.s. |

D

Relative mRNA expression

Hnf4α

E

Necrotic area (%)

Ad-Ctrl | Ad-Hnf4α+APAP | n.s. |

F

ALT release (%)

n.s.

Ad-Ctrl | Ad-Hnf4α+APAP | n.s. |
Figure 5

A

Relative mRNA expression

B

Relative mRNA expression

C

Relative mRNA expression

D

Total GSH (µmol/g total protein)

E

Area (x1000)

F

Area (x1000)